| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1191/0961203305lu2219oa Bisphosphonates and atherosclerosis: why?Endocrine and Diabetes Unit, Ospedale L. Sacco (Vialba)-University of Milan, Italy, mauriziobevilacqua{at}fastwebnet.it
Geriatric Unit, Department of Internal Medicine, University of Palermo, Italy
Abiogen Pharma, Italy
Geriatric Unit, Department of Internal Medicine, University of Palermo, Italy The increasing knowledge on bone calcification processes has revealed some similarities with vascular tissue, where calcifications of arteries and cardiac valves contribute to several cardiovascular problems, such as heart failure, systolic hypertension, and myocardial and peripheral ischemic disease. Bisphosphonates have been used extensively for over two decades for the treatment of diseases associated with excessive bone resorption, i.e., osteoporosis, osteolytic bone metastasis, hypercalcemia and Paget’s disease, by blocking osteoclastic function. Etidronate, pamidronate and clodronate has been shown to inhibit the development of experimental atherosclerosis, and proposed mechanisms for this action include inhibition of arterial calcification and lipid accumulation, degradation of atherogenic LDL-cholesterol and reduced foam cell formation. Bisphosphonates inhibit various enzymes involved in cholesterol biosynthesis and suppress macrophages in atheromatous lesions. The possibility of pharmacological agents that effectively treat both osteoporosis and atherosclerosis is attractive, however, current evidence is not conclusive and further research is necessary to confirm these actions in the clinical setting.
Key Words: atherosclerosis • bisphosphonates • osteoporosis • vascular calcifications
This article has been cited by other articles:
|
||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
